GILD Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Gilead Sciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$65.01|
|52 Week High||US$74.12|
|52 Week Low||US$57.19|
|1 Month Change||3.77%|
|3 Month Change||7.26%|
|1 Year Change||-2.02%|
|3 Year Change||2.59%|
|5 Year Change||0.19%|
|Change since IPO||10,173.19%|
Recent News & Updates
Top Stocks To Help Prepare For A Recession - We Recommend Gilead Sciences
We think a serious recession is more likely than not, with the signs of crisis and dislocation already showing themselves. In big focus are rates, and the house view is that they'll have to rise more than the market expects to deal with supply shortages. Disposable income could get meaningfully chopped as inflation is also supply side and harder to tackle, and much leverage has been introduced to the economy. It's time to get defensive, thinking of beaten-down stocks with a margin of safety and products that won't decline much during a recession. Our main pick is Gilead, but we also propose Imperial Brands and TeamViewer.
Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|GILD||US Biotechs||US Market|
Return vs Industry: GILD exceeded the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: GILD exceeded the US Market which returned -13.2% over the past year.
|GILD Average Weekly Movement||3.0%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: GILD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: GILD's weekly volatility (3%) has been stable over the past year.
About the Company
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
Gilead Sciences Fundamentals Summary
|GILD fundamental statistics|
Is GILD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GILD income statement (TTM)|
|Cost of Revenue||US$5.59b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||3.60|
|Net Profit Margin||16.43%|
How did GILD perform over the long term?See historical performance and comparison
4.5%Current Dividend Yield
Does GILD pay a reliable dividends?See GILD dividend history and benchmarks
|Gilead Sciences dividend dates|
|Ex Dividend Date||Jun 14 2022|
|Dividend Pay Date||Jun 29 2022|
|Days until Ex dividend||19 days|
|Days until Dividend pay date||34 days|
Does GILD pay a reliable dividends?See GILD dividend history and benchmarks
Is Gilead Sciences undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GILD ($65.01) is trading below our estimate of fair value ($136.01)
Significantly Below Fair Value: GILD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GILD is poor value based on its Price-To-Earnings Ratio (18.1x) compared to the US Biotechs industry average (15.7x).
PE vs Market: GILD is poor value based on its Price-To-Earnings Ratio (18.1x) compared to the US market (14.9x).
Price to Earnings Growth Ratio
PEG Ratio: GILD is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: GILD is overvalued based on its Price-To-Book Ratio (4.1x) compared to the US Biotechs industry average (1.4x).
How is Gilead Sciences forecast to perform in the next 1 to 3 years based on estimates from 26 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GILD's forecast earnings growth (8.4% per year) is above the savings rate (1.9%).
Earnings vs Market: GILD's earnings (8.4% per year) are forecast to grow slower than the US market (12.1% per year).
High Growth Earnings: GILD's earnings are forecast to grow, but not significantly.
Revenue vs Market: GILD's revenue (0.9% per year) is forecast to grow slower than the US market (7.7% per year).
High Growth Revenue: GILD's revenue (0.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GILD's Return on Equity is forecast to be high in 3 years time (28.6%)
How has Gilead Sciences performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GILD has a large one-off loss of $4.3B impacting its March 31 2022 financial results.
Growing Profit Margin: GILD's current net profit margins (16.4%) are higher than last year (1.2%).
Past Earnings Growth Analysis
Earnings Trend: GILD's earnings have declined by 22.6% per year over the past 5 years.
Accelerating Growth: GILD's earnings growth over the past year (1400%) exceeds its 5-year average (-22.6% per year).
Earnings vs Industry: GILD earnings growth over the past year (1400%) exceeded the Biotechs industry 96.9%.
Return on Equity
High ROE: Whilst GILD's Return on Equity (22.55%) is high, this metric is skewed due to their high level of debt.
How is Gilead Sciences's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: GILD's short term assets ($12.6B) exceed its short term liabilities ($8.6B).
Long Term Liabilities: GILD's short term assets ($12.6B) do not cover its long term liabilities ($34.6B).
Debt to Equity History and Analysis
Debt Level: GILD's net debt to equity ratio (101.4%) is considered high.
Reducing Debt: GILD's debt to equity ratio has increased from 125.7% to 131.6% over the past 5 years.
Debt Coverage: GILD's debt is well covered by operating cash flow (40.5%).
Interest Coverage: GILD's interest payments on its debt are well covered by EBIT (11.3x coverage).
What is Gilead Sciences's current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: GILD's dividend (4.49%) is higher than the bottom 25% of dividend payers in the US market (1.57%).
High Dividend: GILD's dividend (4.49%) is in the top 25% of dividend payers in the US market (4.06%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, GILD has been paying a dividend for less than 10 years.
Growing Dividend: GILD's dividend payments have increased, but the company has only paid a dividend for 7 years.
Earnings Payout to Shareholders
Earnings Coverage: At its current payout ratio (79.5%), GILD's payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (36.8%), GILD's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dan O'Day (57 yo)
Mr. Daniel P. O'Day, also known as Dan, serves as Non-Executive Non-Independent Director for Galapagos NV. He served as Member of Supervisory Board at Galapagos NV since October 22, 2019 until April 2022....
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD19.23M) is above average for companies of similar size in the US market ($USD13.26M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
Experienced Management: GILD's management team is considered experienced (2.8 years average tenure).
Experienced Board: GILD's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Gilead Sciences, Inc.'s employee growth, exchange listings and data sources
- Name: Gilead Sciences, Inc.
- Ticker: GILD
- Exchange: NasdaqGS
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$81.543b
- Shares outstanding: 1.25b
- Website: https://www.gilead.com
Number of Employees
- Gilead Sciences, Inc.
- 333 Lakeside Drive
- Foster City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.